Hepatitis C virus genotype 4 with normal transaminases: Histological changes, schistosomiasis and response to treatment

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Derbala, M F ^a   Amer, A M ^b   Almohanadi, M ^c   John, A ^c,c   Amin, A ^c   Sharma, M ^c   Alkaabi, S R ^c   Al Dweik, N Z ^c   Pasic, F ^c   Yaqoob, R ^c   Butt, M T ^c   Shebl, F M ^d,e  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b Hematology Section   (United States)

^c HAMAD GENERAL HOSPITAL   (Qatar)

^d NATIONAL CANCER INSTITUTE   (United States)

^e National Liver Institute   (Egypt)

Author keywords

HCV; persistently normal alanine aminotransferase; response to treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GENOTYPE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPHIL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHISTOSOMIASIS; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SCHISTOSOMIASIS; TRANSAMINASES; TREATMENT OUTCOME;

EID: 79959618797     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01403.x     Document Type: Review

References (25)

1. Kamal SM, Nasser IA,. Hepatitis C genotype 4: what we know and what we don't yet know Hepatology 2008; 47 (4): 1371-1383. (Pubitemid 351547923)
2. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-467. (Pubitemid 46944469)
3. Puoti C, Bellis L, Guarisco R, Dell'Unto O, Spilabotti L, Costanza OM,. HCV carriers with normal alanine aminotransferase levels: healthy persons or severely ill patients? Dealing with an everyday clinical problem. Eur J Intern Med 2010; 21: 57-61.
4. Sanai FM, Benmousa A, Al-Hussaini H, et al. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int 2008; 28: 1011-1018.
5. Abdel-Hadi AM, Talaat M,. Histological assessment of tissue repair after treatment of human schistosomiasis. Acta Trop 2000; 77: 91-96.
6. Kamal S, Madwar M, Bianchi L, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281-289. (Pubitemid 30488534)
7. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891. (Pubitemid 30137669)
8. Strickland GT,. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43: 915-922. (Pubitemid 43724616)
9. Magder LS, Fix AD, Mikhail NN, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005; 34: 160-165. (Pubitemid 40347388)
10. Shebl FM, El-Kamary SS, Saleh DA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009; 81: 1024-1031.
11. Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 102-107. (Pubitemid 43024765)
12. Saleh DA, Shebl F, Abdel-Hamid M, et al. Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg 2008; 102: 921-928.
13. Lee YS, Yoon SK, Chung ES, et al. The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J?Korean Med Sci 2001; 16: 585-591. (Pubitemid 33741666)
14. Lawson A,. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat 2010; 17: 51-58.
15. Kojima S, Tanaka Y, Enomoto N, Marumo F, Sato C,. Distribution of hepatitis C virus RNA in the liver and its relation to histopathological changes. Liver 1996; 16: 55-60.
16. Singh S, Gupta R, Malhotra V, Sarin SK,. Predictors of histological activity and fibrosis in chronic hepatitis C infection: a study from North India. Indian J Pathol Microbiol 2010; 53: 238-243.
17. Yagura M, Tanaka A, Kamitsukasa H, Otsuka H, Kanno S, Aoyama T,. Re-evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients. Intern Med 2010; 49: 525-528.
18. Puoti C, Pellicelli AM, Romano M, et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-1484.
19. Snoeck E, Hadziyannis SJ, Puoti C, et al. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin. Liver Int 2008; 28: 61-71.
20. PaweÅczyk A, PolaÅska M, Kisiel E, et al. Replication of HCV in bone marrow of patients with haematological disorders. Przegl Epidemiol 2009; 63 (1): 29-33.
21. Abbas OM, Abdel-Rahman MH, Omar NA, Badran HM, Amir EM,. Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni coinfection. Liver Int 2009; 29: 1422-1430.
22. Eissa LA, Gad LS, Rabie AM, El-Gayar AM,. Thrombopoietin level in patients with chronic liver diseases. Ann Hepatol 2008; 7: 235-244.
23. Correia MC, Domingues AL, Lacerda HR, et al. Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. Trans R Soc Trop Med Hyg 2009; 103: 1053-1058.
24. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135 (2): 451-458.
25. Lindh M, Arnholm B, Eilard A, et al. Hepatitis C treatment response kinetics and impact of baseline predictors. J Viral Hepat 2010; May 25 [Epub ahead of print].